NCT05424692 Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
| NCT ID | NCT05424692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Colon Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-09-01 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2021-09-01 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
Eligibility Criteria
Inclusion Criteria: * Age 18 \~ 75 years old, regardless of gender * Patients with colorectal cancer diagnosed by histopathology or cytology * Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy * Having at least one assessable tumor focus * ECoG physical condition score ≤ 2 points * Voluntarily participate and sign informed consent Exclusion Criteria: * Patients diagnosed with metastasis * Patients who cannot obtain tumor samples * Pregnant and lactating women * Patients with poor compliance * Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment * Patients with other malignant tumors * Suffering from serious mental and nervous system diseases * The researchers believe that patients should not be selected for this study
Contact & Investigator
Guole Lin
STUDY CHAIR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT05424692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Colon Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05424692 currently recruiting?
Yes, NCT05424692 is actively recruiting participants. Contact the research team at linguole@126.com for enrollment information.
Where is the NCT05424692 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05424692 clinical trial?
NCT05424692 is sponsored by Peking Union Medical College Hospital. The principal investigator is Guole Lin at Peking Union Medical College Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.